For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) ...

The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after ...

The benefit was confined to symptoms, but in a very sick population with few options, that’s important, say researchers.

Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid ...

For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement ...

New analyses bolster the case for tricuspid TEER and reassure on outcomes in patients with implanted electronic devices.

Edwards Lifesciences (NYSE:EW) today announced data highlighting the superiority of its Evoque system compared to medical ...

Amir Danino, CEO of Innoventric, stated: “Our mission is to revolutionize tricuspid regurgitation care with minimally invasive therapies that significantly improve patient outcomes. The strong backing ...

Sandra Lesenfants, senior vice president of Abbott’s Structural Heart business, shares an update on MitraClip, TriClip, and ...

In this cohort study, the Kansas City Cardiomyopathy Questionnaire (KCCQ) had strong psychometric properties in patients with ...

Israeli heart medical device company Innoventric today announced the completion of a $28.5 million Series B financing round.

Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed.